Abstracts tagged "Biologicals"

Abstract Number: 2123 • ACR Convergence 2022
Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis
Jesus Diaz¹, Guillermo Quiceno² and Adela Castro³, ¹Hamilton Medical Center, Chattanooga, TN, ²UT Southwestern Medical Center, Dallas, TX, ³Hamilton Physician Group-Specialty Care, Dalton, GA
Background/Purpose: There are an increasing number of biological and targeted DMARDs in PsA. However, challenges around treatment selection remain, given the few head-to-head studies directly…
Abstract Number: 2251 • ACR Convergence 2022
Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Matthew Baker¹, Yuhan Liu¹, Rong Lu¹, Janice Lin¹, Jason Melehani¹ and William Robinson², ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…
Abstract Number: 0197 • ACR Convergence 2022
Is Similar the Same? How We Incorporated Feedback from 250 Patients into a CME Activity on Biosimilars
Stephen Bender¹ and Suzanne Schrandt², ¹FACTORx, Cherry Hill, NJ, ²ExPPect, Arlington, VA
Background/Purpose: The goals of this project were two-fold: The primary goal was to provide clinicians who treat rheumatoid arthritis (RA) and inflammatory bowel disease (IBD)…
Abstract Number: 0347 • ACR Convergence 2022
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
Christopher Bell¹, Bernie Rubin², Karen Worley³, Guillaume Germain⁴, François Laliberté⁴, Sean D. MacKnight⁴, Ana Urosevic⁴ and Mei Sheng Duh⁵, ¹GlaxoSmithKline, US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ³GlaxoSmithKline, US Value, Evidence and Outcomes, Cincinnati, OH, ⁴Groupe d’analyse, Montréal, QC, Canada, ⁵Analysis Group Inc, Boston, MA
Background/Purpose: The aim of this study was to evaluate the real-world effectiveness of the disease-modifying treatment belimumab (BEL), comparing the rates of SLE flares among…
Abstract Number: 0429 • ACR Convergence 2022
No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis
Mark Siderius¹, Suzanne Arends², Freke Wink³ and Anneke Spoorenberg², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: In patients with ankylosing spondylitis (AS), TNF-α inhibitors influence the course of serum bone turnover markers (BTM), favoring an increase in mineralization during the…
Abstract Number: 0768 • ACR Convergence 2022
Reevaluating Clinical Outcomes of Patients on Combination Biologics
Ryan Mathew¹, Alexa Meara², ChienWei Chiang³, Komal Paradakar³, Ambra Burrell³ and Gabriel Kirsch³, ¹The Ohio State University Medical Center, Skokie, IL, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Biologic treatments such as monoclonal antibodies have become first line treatment for many autoimmune diseases and now monoclonal antibodies are being used to treated…
Abstract Number: 0879 • ACR Convergence 2022
Golimumab for Treatment of Polyarticular Juvenile Idiopathic Arthritis – Safety and Effectiveness Updates from a Comparative Study
Angela Zimmer¹, Ariane Klein¹ and Gerd Horneff², ¹Asklepios, St. Augustin, Germany, ²Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany
Background/Purpose: Golimumab (GOL) is approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years and older. Data on long-term safety and…
Abstract Number: 1039 • ACR Convergence 2022
Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study
Guillaume LARID¹, Guy Baudens², Alexis DANDURAND¹, Pascal COQUERELLE³, Vincent Goeb⁴, Marie-Hélène Guyot⁵, Laurent Marguerie⁶, Frédéric MAURY⁷, Viellard Eric⁸, Eric Houvenagel⁹, Jean Hugues SALMON¹⁰, René-Marc Flipo¹¹ and elisabeth gervais¹, ¹CHU Poitiers, Poitiers, France, ²Private practice, Valenciennes, France, ³CH Béthune, Béthune, France, ⁴CHU Amiens, Amiens, France, ⁵Private practice, Roubaix, France, ⁶Institut Calot, Berck-Sur-Mer, France, ⁷Private practice, Béthune, France, ⁸Private practice, St. Malo, France, ⁹Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, ¹⁰Reims University Hospital, Reims, France, ¹¹CHU Lille, Boulogne-Billancourt, France
Background/Purpose: Studies have demonstrated equivalence in term of efficacy and safety of biosimilars (bsDMARDs) compared to the originals treatments (boDMARDs) and in switching situation. Less…
Abstract Number: 1396 • ACR Convergence 2022
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Masayoshi Harigai¹, Takao Fujii², Ryoko Sakai³, Ataru Igarashi⁴, Ayako Shoji⁵, Hiroko Yamaguchi⁶, Katsuhiko Iwasaki⁶, Misako Makishima⁷, Amika Yoshida⁷, Norihiro Okada⁷, Katsuhisa Yamashita⁷ and Yutaka Kawahito⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, ³Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan, ⁴Department of Health Economics & Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan; Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine, Kanagawa, Japan, ⁵Medilead Inc., Tokyo, Japan; Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; Healthcare Consulting Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁶Medilead Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁷Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, ⁸Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan
Background/Purpose: Safety evidence of biological or targeted synthetic DMARDs (b/tsDMARDs) is still insufficient in older elderly ( >=75 years old (y/o)) patients with rheumatoid arthritis…
Abstract Number: 1556 • ACR Convergence 2022
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Alba Herrero-Morant¹, José Luis Martín-Varillas², Santos Castañeda³, Olga Maiz⁴, Julio Sánchez-Martín⁵, Norberto Ortego⁶, Enrique Raya⁷, Águeda Prior-Español⁸, Clara Moriano⁹, Rafael Melero¹⁰, Genaro Graña-Gil¹¹, Ana Urruticoechea¹², Angel Ramos¹³, Marta Loredo-Martínez¹⁴, Eva Salgado-Pérez¹⁵, Francisca Sivera¹⁶, Ignacio Torre¹⁷, F. Javier Narváez¹⁸, Jose Luis Andreu¹⁹, Olga Martinez²⁰, Ricardo Gómez-de la Torre²¹, Sabela Fernandez-Aguado²², Susana Romero Yuste²³, iñigo Gonzalez-Mazon⁵, Carmen Alvarez Reguera⁵, David Martínez-López⁵, José Luis Hernández⁵, Miguel Ángel González-Gay²⁴ and Ricardo Blanco²⁵, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital de Laredo, Laredo, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Hospital Universitario de Donostia, San Sebastián, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Medicine Department, Universidad de Granada, Granada, Spain, ⁷Hospital San Cecilio, Granada, Spain, ⁸Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁹Complejo Asistencial Universitario de León, León, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ¹¹Hospital Universitario de A Coruña, A Coruña, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Complejo Hospitalario de Soria, Soria, Spain, ¹⁴Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹⁵Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, ¹⁶Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁷Hospital de Basurto, Basurto, Spain, ¹⁸Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁰Hospital Clínico Universitario de Salamanca, Zamora, Spain, ²¹Hospital Universitario Central de Asturias, Oviedo, Spain, ²²Hospital Universitario de Cabueñes, Gijon, Spain, ²³Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…
Abstract Number: 1980 • ACR Convergence 2022
Seroconversion After a Third COVID-19 Vaccination in Rheumatoid Arthritis Patients Treated with (ultra-)low Dose Rituximab with a Previous Insufficient Humoral Response Is Associated with Rituximab Dosage
Céleste van der Togt¹, David Ten Cate¹, Janette Rahamat-Langendoen², Bart van den Bemt³, Nathan den Broeder⁴ and Alfons den Broeder⁴, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²ErasmusMC, Rotterdam, Zuid-Holland, Netherlands, ³Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Around 60% of rheumatoid arthritis (RA) patients treated with ≥1000 mg rituximab (RTX) has an insufficient deemed humoral response after two COVID-19 vaccinations. Recent…
Abstract Number: 2129 • ACR Convergence 2022
Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Signe Holm Nielsen¹, Anne-Christine Bay-Jensen¹, Peder Frederiksen¹, Morten Karsdal¹, May Shawi², Soumya Chakravarty³, Alexa Kollmeier⁴, Warner Chen⁵ and Sheng Gao⁵, ¹Nordic Bioscience, Herlev, Denmark, ²Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁴Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁵Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Psoriatic arthritis (PsA) is a progressive, joint-degenerative inflammatory disease with cartilage destruction, bone erosion and growth, and synovitis. Extracellular matrix (ECM) remodeling is also…
Abstract Number: 2259 • ACR Convergence 2022
Complete Resolution of Inflammation on MRI Is Associated with a Better Clinical Response over Time in Patients with Early Axial Spondyloarthritis
valeria Rios-Rodriguez¹, Murat Torgutalp², Christian Althoff³, Hildrun Haibel², Kay-Geert Hermann², Fabian Proft⁴, Mikhail Protopopov⁵, Judith Rademacher⁵, Joachim Sieper² and Denis Poddubnyy⁴, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Helios Klinikum Emil von Behring, Berlin, Germany, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Magnetic resonance imaging (MRI) of the spine and sacroiliac joints (SIJ) are important tools for the diagnosis of axial SpA and the presence of…
Abstract Number: 0199 • ACR Convergence 2022
Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
Peter Taylor¹, Frank Behrens², Philip J Mease³, Dieter Wetzel⁴, Paul Peloso⁵, Nicolai Brun⁴, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowińska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Kurt de Vlam¹², ¹University of Oxford, Oxford, United Kingdom, ²Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Affibody AB, Solna, Sweden, ⁵ACELYRIN, Naples, FL, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network - Rheumatology, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²University Hospitals Leuven, Leuven, Belgium
Background/Purpose: Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a…
Abstract Number: 0348 • ACR Convergence 2022
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Rachel Kneeland¹, Daniel Montes¹, Justin endo¹, Bridget Shields¹, Christie Bartels² and Shivani Garg³, ¹University of Wisconsin, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause significant scarring and psychological distress. Belimumab, a monoclonal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].